vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Ecovyst Inc.（ECVT）财务数据对比。点击上方公司名可切换其他公司
Ecovyst Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.1倍（$199.4M vs $183.1M），Ecovyst Inc.同比增速更快（34.0% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $22.9M），过去两年Ecovyst Inc.的营收复合增速更高（18.7% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Ecovyst Inc.是一家全球可持续特种材料供应商，主营高性能催化剂与功能性添加剂的研发、生产，产品服务覆盖工业制造、消费品、环保等核心领域，助力全球客户提升运营效率、降低碳排放。
AMPH vs ECVT — 直观对比
营收规模更大
ECVT
是对方的1.1倍
$183.1M
营收增速更快
ECVT
高出35.8%
-1.8%
自由现金流更多
AMPH
多$1.6M
$22.9M
两年增速更快
ECVT
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $199.4M |
| 净利润 | $24.4M | — |
| 毛利率 | 46.8% | 23.4% |
| 营业利润率 | 19.4% | 10.9% |
| 净利率 | 13.3% | — |
| 营收同比 | -1.8% | 34.0% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHECVT
| Q4 25 | $183.1M | $199.4M | ||
| Q3 25 | $191.8M | $204.9M | ||
| Q2 25 | $174.4M | $176.1M | ||
| Q1 25 | $170.5M | $143.1M | ||
| Q4 24 | $186.5M | $148.9M | ||
| Q3 24 | $191.2M | $153.9M | ||
| Q2 24 | $182.4M | $154.0M | ||
| Q1 24 | $171.8M | $141.6M |
净利润AMPHECVT
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-79.3M | ||
| Q2 25 | $31.0M | $6.0M | ||
| Q1 25 | $25.3M | $-3.6M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $14.3M | ||
| Q2 24 | $37.9M | $8.3M | ||
| Q1 24 | $43.2M | $1.2M |
毛利率AMPHECVT
| Q4 25 | 46.8% | 23.4% | ||
| Q3 25 | 51.4% | 25.4% | ||
| Q2 25 | 49.6% | 22.8% | ||
| Q1 25 | 50.0% | 13.3% | ||
| Q4 24 | 46.5% | 28.9% | ||
| Q3 24 | 53.3% | 29.3% | ||
| Q2 24 | 52.2% | 27.3% | ||
| Q1 24 | 52.4% | 23.5% |
营业利润率AMPHECVT
| Q4 25 | 19.4% | 10.9% | ||
| Q3 25 | 13.2% | 13.8% | ||
| Q2 25 | 24.2% | 9.0% | ||
| Q1 25 | 21.9% | -0.7% | ||
| Q4 24 | 24.2% | 15.1% | ||
| Q3 24 | 29.8% | 17.9% | ||
| Q2 24 | 30.3% | 14.1% | ||
| Q1 24 | 27.9% | 9.5% |
净利率AMPHECVT
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -38.7% | ||
| Q2 25 | 17.8% | 3.4% | ||
| Q1 25 | 14.8% | -2.5% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 9.3% | ||
| Q2 24 | 20.8% | 5.4% | ||
| Q1 24 | 25.1% | 0.9% |
每股收益（稀释后）AMPHECVT
| Q4 25 | $0.51 | $0.06 | ||
| Q3 25 | $0.37 | $-0.69 | ||
| Q2 25 | $0.64 | $0.05 | ||
| Q1 25 | $0.51 | $-0.03 | ||
| Q4 24 | $0.74 | $-0.26 | ||
| Q3 24 | $0.78 | $0.12 | ||
| Q2 24 | $0.73 | $0.07 | ||
| Q1 24 | $0.81 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $197.2M |
| 总债务越低越好 | $608.7M | $392.6M |
| 股东权益账面价值 | $788.8M | $603.4M |
| 总资产 | $1.6B | $1.3B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.65× |
8季度趋势，按日历期对齐
现金及短期投资AMPHECVT
| Q4 25 | $282.8M | $197.2M | ||
| Q3 25 | $276.2M | $82.0M | ||
| Q2 25 | $231.8M | $69.6M | ||
| Q1 25 | $236.9M | $127.5M | ||
| Q4 24 | $221.6M | $131.4M | ||
| Q3 24 | $250.5M | $123.5M | ||
| Q2 24 | $217.8M | $83.3M | ||
| Q1 24 | $289.6M | $103.1M |
总债务AMPHECVT
| Q4 25 | $608.7M | $392.6M | ||
| Q3 25 | $608.6M | $854.8M | ||
| Q2 25 | $607.7M | $856.6M | ||
| Q1 25 | $603.9M | $859.0M | ||
| Q4 24 | $601.6M | $860.8M | ||
| Q3 24 | $596.4M | $862.7M | ||
| Q2 24 | $586.9M | $862.4M | ||
| Q1 24 | $594.0M | $866.2M |
股东权益AMPHECVT
| Q4 25 | $788.8M | $603.4M | ||
| Q3 25 | $776.7M | $607.9M | ||
| Q2 25 | $757.5M | $692.4M | ||
| Q1 25 | $751.3M | $698.7M | ||
| Q4 24 | $732.3M | $700.5M | ||
| Q3 24 | $727.7M | $729.4M | ||
| Q2 24 | $713.3M | $717.3M | ||
| Q1 24 | $672.4M | $711.4M |
总资产AMPHECVT
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.8B | ||
| Q1 25 | $1.6B | $1.8B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.5B | $1.8B | ||
| Q1 24 | $1.6B | $1.8B |
负债/权益比AMPHECVT
| Q4 25 | 0.77× | 0.65× | ||
| Q3 25 | 0.78× | 1.41× | ||
| Q2 25 | 0.80× | 1.24× | ||
| Q1 25 | 0.80× | 1.23× | ||
| Q4 24 | 0.82× | 1.23× | ||
| Q3 24 | 0.82× | 1.18× | ||
| Q2 24 | 0.82× | 1.20× | ||
| Q1 24 | 0.88× | 1.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $41.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $22.9M |
| 自由现金流率自由现金流/营收 | 13.4% | 11.5% |
| 资本支出强度资本支出/营收 | 4.5% | 9.4% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $69.9M |
8季度趋势，按日历期对齐
经营现金流AMPHECVT
| Q4 25 | $32.9M | $41.8M | ||
| Q3 25 | $52.6M | $55.3M | ||
| Q2 25 | $35.6M | $33.0M | ||
| Q1 25 | $35.1M | $10.3M | ||
| Q4 24 | $29.0M | $43.5M | ||
| Q3 24 | $60.0M | $59.9M | ||
| Q2 24 | $69.1M | $10.0M | ||
| Q1 24 | $55.3M | $36.5M |
自由现金流AMPHECVT
| Q4 25 | $24.6M | $22.9M | ||
| Q3 25 | $47.2M | $53.2M | ||
| Q2 25 | $25.0M | $7.8M | ||
| Q1 25 | $24.4M | $-14.0M | ||
| Q4 24 | $16.6M | $30.9M | ||
| Q3 24 | $46.2M | $53.6M | ||
| Q2 24 | $63.1M | $-9.3M | ||
| Q1 24 | $46.5M | $19.1M |
自由现金流率AMPHECVT
| Q4 25 | 13.4% | 11.5% | ||
| Q3 25 | 24.6% | 26.0% | ||
| Q2 25 | 14.3% | 4.4% | ||
| Q1 25 | 14.3% | -9.8% | ||
| Q4 24 | 8.9% | 20.7% | ||
| Q3 24 | 24.1% | 34.9% | ||
| Q2 24 | 34.6% | -6.1% | ||
| Q1 24 | 27.1% | 13.5% |
资本支出强度AMPHECVT
| Q4 25 | 4.5% | 9.4% | ||
| Q3 25 | 2.8% | 1.0% | ||
| Q2 25 | 6.1% | 14.4% | ||
| Q1 25 | 6.3% | 16.9% | ||
| Q4 24 | 6.7% | 8.5% | ||
| Q3 24 | 7.2% | 4.1% | ||
| Q2 24 | 3.3% | 12.5% | ||
| Q1 24 | 5.1% | 12.3% |
现金转化率AMPHECVT
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 5.52× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 4.21× | ||
| Q2 24 | 1.82× | 1.20× | ||
| Q1 24 | 1.28× | 29.90× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
